Last updated: June 23, 2026
Astellas v. Actavis Elizabeth LLC (1:16-cv-00905) Patent Litigation Summary and Analysis
Astellas Pharma Inc. sued Actavis Elizabeth LLC in the District of New Jersey over branded prescription drug IP and asserted patent infringement. The case is docketed as Astellas Pharma Inc. v. Actavis Elizabeth LLC, No. 1:16-cv-00905. The core business impact is exclusivity risk allocation between the reference product and Actavis’s intended commercial launch, with the infringement claims typically focused on Orange Book-listed patents and the asserted asserted claims defining scope of protected subject matter.
What happened in Astellas v. Actavis Elizabeth LLC 1:16-cv-00905?
Case docket: Astellas Pharma Inc. v. Actavis Elizabeth LLC, 1:16-cv-00905 (District of New Jersey).
Litigation posture (generic launch context): The suit is consistent with Hatch-Waxman paragraph IV-style infringement litigation where the brand owner targets a generic filer prior to approval and/or launch.
What did Astellas allege Actavis infringed?
In this case class, the claims are generally directed to one or more of:
- Composition-of-matter or formulation patents covering the active drug substance, polymorphs, salts, hydrates, or specific formulation parameters (for example, particle size distributions, excipients, dissolution characteristics).
- Method-of-use patents tied to a labeled therapeutic regimen.
- Manufacturing or process patents covering steps for producing the drug substance or final dosage form.
How did Actavis respond?
Actavis’s standard defenses in this posture typically include:
- Non-infringement (no practice of the asserted claims).
- Invalidity (anticipation, obviousness, lack of enablement, indefiniteness).
- Statutory defenses tied to the FDA carve-outs or non-covered uses.
Which patents were at issue in Astellas v. Actavis Elizabeth LLC 1:16-cv-00905?
A complete and accurate patent-by-patent mapping is not provided in the input. The docket caption alone (without the complaint, claim list, Markman orders, or infringement claim chart) is insufficient to identify:
- asserted patent numbers,
- expiration dates,
- claim sets,
- and claim construction outcomes.
Because the requested deliverable is a litigation summary and analysis, the patent identification is essential to support any infringement/validity conclusions.
What court ruled in Astellas v. Actavis Elizabeth LLC 1:16-cv-00905?
The input does not include:
- motion outcomes,
- claim construction rulings,
- summary judgment results,
- trial verdict or settlement docket entries,
- or the final judgment.
Without these items, any description of “what the court ruled” would be incomplete and potentially inaccurate.
How does 1:16-cv-00905 fit into Hatch-Waxman Paragraph IV strategy and generic entry risk?
What is the typical business mechanism in this litigation type?
For brand owners, the enforcement theory is to stop or delay approval and market entry by obtaining:
- injunctive relief (rare if resolved on timing),
- early dismissal based on non-infringement or invalidity,
- summary judgment,
- or a settlement tied to a launch date.
For generic manufacturers, the parallel objective is:
- to invalidate the asserted patents,
- to narrow claim construction so the generic does not meet claim limitations,
- or to reach a settlement that preserves margin via earlier entry.
What does the case number imply about timeline and process?
A suit filed in 2016 generally aligns with:
- an FDA approval milestone (or a Paragraph IV filing triggering litigation),
- an initial pleading and early Markman timeline,
- potential outcomes through claim construction and dispositive motions,
- then settlement or final resolution.
But specific dates and milestones require docket text or orders.
Did Astellas and Actavis reach a settlement in 1:16-cv-00905?
The input does not include settlement terms, consent judgments, dismissals, or timing commitments.
Settlement analysis in particular depends on:
- whether the case settled before claim construction,
- whether there was a “to be agreed” launch date,
- whether there were exclusivity licensing rights,
- and whether there were covenants not to sue tied to specified launch/labeling/manufacturing changes.
What was the litigation impact on FDA approval and market launch?
Litigation impact is assessed via:
- whether Actavis entered “at risk” during the pendency,
- whether there was a temporary restraining order or preliminary injunction,
- whether FDA approval was stayed,
- and whether the generic launch date matched settlement terms.
No FDA linkage is included in the prompt, so the impact cannot be computed or stated.
How strong was Astellas’s patent estate versus Actavis’s non-infringement and invalidity positions?
A “strength” analysis normally requires:
- identification of asserted patents,
- their claim scope,
- the prior art set cited in invalidity motions,
- claim construction results,
- and the final disposition.
None of these inputs are present. Providing a strength score or qualitative assessment without the asserted patent list and outcomes would be non-actionable.
Which jurisdictions and regulatory pathways were implicated?
This case is in the U.S. federal district court (District of New Jersey), and the regulatory pathway is almost certainly FDA Hatch-Waxman (ANDA context). But the drug identity and FDA pathway (505(b)(2) vs ANDA) are not stated.
Commercial implications: what revenue exposure and switching dynamics were likely?
Commercial exposure analysis requires:
- the drug’s branded sales during 2014-2019,
- market share and patient segments,
- generic launch timing,
- and any authorized generic provisions.
The input does not identify the product, so the market and revenue mapping cannot be performed.
Key Takeaways
- Case: Astellas Pharma Inc. v. Actavis Elizabeth LLC, 1:16-cv-00905 in the District of New Jersey.
- Litigation type (contextual): Patent infringement litigation tied to a generic launch risk.
- Actionability gap: The input does not contain the asserted patent list, claim construction outcomes, motion results, final judgment, or settlement terms required to produce a complete litigation summary and legal analysis.
FAQs
- What procedural stages occur in Hatch-Waxman infringement cases filed in the District of New Jersey around 2016?
- How do claim construction rulings typically drive non-infringement outcomes in ANDA patent litigations?
- What settlement structures are common after Markman in Astellas versus generic manufacturer disputes?
- How should investors evaluate “at risk” generic launch decisions during ongoing patent litigation?
- What Orange Book patent types (composition, formulation, method-of-use, process) most often dominate infringement theories?
References
- U.S. District Court, District of New Jersey. Astellas Pharma Inc. v. Actavis Elizabeth LLC, No. 1:16-cv-00905 (case docket).
